NeurosciencebioRxivPreprint
In silico transcriptomics identifies FDA-approved drugs and biological pathways for protection against cisplatin-induced hearing loss
Pezhman Salehi, Marisa Zallocchi, Sarath Vijayakumar…·Jian Zuo
The paper uses in silico transcriptomics to identify FDA-approved drugs and pathways that protect against cisplatin-induced hearing loss, validating niclosamide as a potential otoprotectant.